Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 23, 2019
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) with Redstart Holdings Corp. The transaction closed on or about May 30, 2019.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial results. Key metrics related to the transaction include:
- Principal Amount: $133,000.00
- Net Proceeds: $130,000 (intended for general working capital)
- Transaction Fees: $3,000.00 paid to Redstart Holdings Corp.
- Interest Rate: 8% per annum (payable in cash or shares upon maturity/acceleration)
- Default Interest Rate: 22% per annum
- Debt Instrument: Convertible Promissory Note (May 2019 Redstart Note)
Note: The filing text does not provide clear values for total revenue, net profit, operating cash flow, gross margins, or total company debt outside of this specific note.
Material Changes and Transaction Terms
The primary material change is the incurrence of a new direct financial obligation. Key terms of the May 2019 Redstart Note include:
- Maturity Date: May 23, 2020.
- Conversion Rights: Redstart may convert principal to common stock starting November 19, 2019.
- Conversion Price: $0.065, subject to market price adjustments (variable between 65% of Market Price and $0.065 depending on whether Market Price is above or below $0.10).
- Conversion Cap: Restricted if conversion would cause Redstart to beneficially own more than 4.99% of outstanding shares.
- Prepayment Premiums: Significant penalties apply for early prepayment, ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment (60 to 180 days from issuance).
- Default Amount: Upon an event of default, the obligation accelerates to 150% of the outstanding principal plus accrued interest.
Guidance, Risks, and Contingencies
Management Commentary: The Company intends to use net proceeds for general working capital purposes.
Risks and Contingencies:
- Events of Default: Include failure to issue shares upon conversion, breach of covenants, insolvency, bankruptcy, delisting, failure to meet reporting obligations, cessation of operations, or restatement of financial statements with a material adverse effect.
- Penalties: A $1,000 penalty applies if shares are not delivered within three business days of a conversion notice (unless caused by a third party).
- Asset Disposition Restriction: The Company cannot sell or dispose of substantially all assets without Redstart's consent if it would render the Company a "shell company."
- Regulatory Status: The securities were issued in a private placement under Section 4(a)(2) of the Securities Act and/or Regulation D.
Investor Verification Checklist
- Verify the current "Market Price" of PPCB to determine the applicable conversion price under the variable formula.
- Confirm the Company's ability to reserve at least five times the number of shares issuable upon full conversion of the note.
- Review the Company's cash position to assess the ability to meet the 8% interest obligation or potential prepayment premiums if liquidity improves.
- Monitor compliance with reporting obligations under the Exchange Act to avoid triggering a default event.
- Check for any subsequent filings regarding the conversion of the note or acceleration of the debt.